KR20230147751A - 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 - Google Patents

전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 Download PDF

Info

Publication number
KR20230147751A
KR20230147751A KR1020237034341A KR20237034341A KR20230147751A KR 20230147751 A KR20230147751 A KR 20230147751A KR 1020237034341 A KR1020237034341 A KR 1020237034341A KR 20237034341 A KR20237034341 A KR 20237034341A KR 20230147751 A KR20230147751 A KR 20230147751A
Authority
KR
South Korea
Prior art keywords
group
cells
alkyl
tumors
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237034341A
Other languages
English (en)
Korean (ko)
Inventor
산지타 레이
마틴 지. 펌퍼
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Priority to KR1020257012794A priority Critical patent/KR20250057132A/ko
Publication of KR20230147751A publication Critical patent/KR20230147751A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237034341A 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 Ceased KR20230147751A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257012794A KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
KR1020227015010A KR20220063298A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015010A Division KR20220063298A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257012794A Division KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Publications (1)

Publication Number Publication Date
KR20230147751A true KR20230147751A (ko) 2023-10-23

Family

ID=59899817

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237034341A Ceased KR20230147751A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020227015010A Ceased KR20220063298A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020187030310A Active KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020257012794A Pending KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227015010A Ceased KR20220063298A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020187030310A Active KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020257012794A Pending KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Country Status (27)

Country Link
US (3) US11458213B2 (enExample)
EP (3) EP3925952B1 (enExample)
JP (3) JP7073270B2 (enExample)
KR (4) KR20230147751A (enExample)
CN (3) CN114716387B (enExample)
AU (1) AU2017238181B2 (enExample)
BR (1) BR112018069507A2 (enExample)
CA (1) CA3018709A1 (enExample)
CL (1) CL2018002683A1 (enExample)
CY (1) CY1124487T1 (enExample)
DK (2) DK3925952T3 (enExample)
ES (2) ES2972148T3 (enExample)
FI (1) FI3925952T3 (enExample)
HR (2) HRP20240215T1 (enExample)
HU (2) HUE055607T2 (enExample)
LT (2) LT3925952T (enExample)
MX (1) MX384823B (enExample)
PH (1) PH12018502048A1 (enExample)
PL (2) PL3433238T3 (enExample)
PT (2) PT3925952T (enExample)
RS (2) RS65188B1 (enExample)
RU (2) RU2021115958A (enExample)
SA (1) SA518400103B1 (enExample)
SI (2) SI3433238T1 (enExample)
TR (1) TR201813644T1 (enExample)
WO (1) WO2017165473A1 (enExample)
ZA (1) ZA201806389B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031809A1 (en) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
EP3544960A1 (en) * 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
CN110291401B (zh) 2016-12-14 2023-04-11 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2019115547A1 (en) * 2017-12-11 2019-06-20 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
PL3498308T3 (pl) * 2017-12-13 2025-03-31 Sciencons AS Kompleks zawierający związek celujący w PSMA połączony z radionuklidem ołowiu lub toru
KR20250021601A (ko) * 2018-02-06 2025-02-13 우니베르시타트 하이델베르크 Fap 억제제
BR112020016040A2 (pt) * 2018-02-06 2020-12-08 The Johns Hopkins University Ureia-poliaminocarboxilatos radiohalogenados que utilizam psma como alvo para radioterapia contra câncer
SG11202009649RA (en) 2018-03-30 2020-10-29 Futurechem Co Ltd Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
AU2019287595B2 (en) * 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
BR112021005931A2 (pt) * 2018-09-28 2021-06-29 Universität Heidelberg composto, complexo e composição farmacêutica
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
WO2020139012A1 (ko) * 2018-12-27 2020-07-02 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
JP7608378B2 (ja) * 2019-07-02 2025-01-06 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN120441497A (zh) * 2019-07-02 2025-08-08 先进加速器应用意大利公司 前列腺特异性膜抗原（psma）配体及其用途
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
WO2021219719A1 (en) 2020-04-29 2021-11-04 Advanced Accelerator Applications (Italy) Srl Methods for radiolabelling psma binding ligands and their kits
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022101352A1 (en) 2020-11-12 2022-05-19 Abx Advanced Biochemical Compounds Gmbh Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
EP4247798B1 (en) * 2020-11-19 2025-08-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
WO2022266499A1 (en) * 2021-06-17 2022-12-22 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
JP2025506001A (ja) 2022-02-09 2025-03-05 ノバルティス アーゲー ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物
EP4637843A2 (en) * 2022-12-21 2025-10-29 Mayo Foundation for Medical Education and Research Methods and materials for combining biologics with multiple chelators
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5680409B2 (ja) * 2007-06-26 2015-03-04 ザ ジョンズ ホプキンス ユニバーシティ 前立腺特異膜抗原（ｐｓｍａ）の標識阻害剤、生物学的評価およびイメージング剤としての使用
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
AU2009322171A1 (en) * 2008-12-05 2011-06-30 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
CA3257131A1 (en) * 2009-03-19 2025-04-15 The Johns Hopkins University PSMA-TARGETING COMPOUNDS AND RELATED USES
ES2732060T3 (es) * 2011-08-05 2019-11-20 Molecular Insight Pharm Inc Inhibidores radiomarcados del antígeno de membrana específico de la próstata
CN113149921B (zh) * 2011-11-30 2024-11-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
PL2943227T3 (pl) * 2013-01-14 2018-02-28 Molecular Insight Pharmaceuticals, Inc. Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN111285918B (zh) * 2014-05-06 2024-05-31 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Also Published As

Publication number Publication date
US20230015736A1 (en) 2023-01-19
PT3433238T (pt) 2021-07-28
PL3925952T3 (pl) 2024-04-22
RU2018133693A3 (enExample) 2020-04-22
HUE065327T2 (hu) 2024-05-28
JP2019519467A (ja) 2019-07-11
US11458213B2 (en) 2022-10-04
SI3433238T1 (sl) 2021-11-30
BR112018069507A2 (pt) 2019-01-29
WO2017165473A1 (en) 2017-09-28
CY1124487T1 (el) 2022-07-22
CN114716387B (zh) 2025-04-01
LT3433238T (lt) 2021-09-27
PL3433238T3 (pl) 2021-12-13
RS62274B1 (sr) 2021-09-30
KR20220063298A (ko) 2022-05-17
JP2022116028A (ja) 2022-08-09
ES2972148T3 (es) 2024-06-11
RS65188B1 (sr) 2024-03-29
PT3925952T (pt) 2023-12-13
DK3925952T3 (da) 2024-02-05
CN114716387A (zh) 2022-07-08
EP4385981A1 (en) 2024-06-19
EP3925952B1 (en) 2023-11-29
CN120172884A (zh) 2025-06-20
SA518400103B1 (ar) 2022-03-20
HRP20211386T1 (hr) 2021-12-10
JP7073270B2 (ja) 2022-05-23
LT3925952T (lt) 2024-01-25
US20200155713A1 (en) 2020-05-21
EP3925952A1 (en) 2021-12-22
EP3433238B1 (en) 2021-06-16
US20250195700A1 (en) 2025-06-19
CA3018709A1 (en) 2017-09-28
RU2018133693A (ru) 2020-04-22
MX2018011519A (es) 2019-01-28
KR102396307B1 (ko) 2022-05-09
NZ786380A (en) 2025-05-02
CN109311827A (zh) 2019-02-05
ZA201806389B (en) 2024-01-31
HUE055607T2 (hu) 2021-12-28
CL2018002683A1 (es) 2019-04-22
AU2017238181A1 (en) 2018-10-18
KR20250057132A (ko) 2025-04-28
AU2017238181B2 (en) 2021-05-27
RU2749399C2 (ru) 2021-06-09
EP3433238A4 (en) 2019-09-11
HRP20240215T1 (hr) 2024-04-26
DK3433238T3 (da) 2021-09-06
SI3925952T1 (sl) 2024-03-29
TR201813644T1 (tr) 2018-11-21
ES2877572T3 (es) 2021-11-17
NZ746701A (en) 2024-12-20
RU2021115958A (ru) 2021-07-12
PH12018502048A1 (en) 2019-07-01
MX384823B (es) 2025-03-14
KR20180134918A (ko) 2018-12-19
FI3925952T3 (fi) 2024-02-13
JP2024050608A (ja) 2024-04-10
EP3433238A1 (en) 2019-01-30
CN109311827B (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
KR102396307B1 (ko) 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
BR112020016040A2 (pt) Ureia-poliaminocarboxilatos radiohalogenados que utilizam psma como alvo para radioterapia contra câncer
KR102531494B1 (ko) 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도
US20200231614A1 (en) Psma targeted radiohalogenated ureas for cancer radiotherapy
US20210338846A1 (en) Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2016149188A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
BR122025009780A2 (pt) Compostos, método para tratar uma ou mais células ou tumores que expressam psma in vitro ou ex vivo que utiliza os ditos compostos e uso dos mesmos para tratar tumores ou células que expressam psma
US10912850B2 (en) 18F-FNDP for pet imaging of soluble epoxide hydrolase (sEH)

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231006

Application number text: 1020227015010

Filing date: 20220503

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231114

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D